Geron Corp Stock Prediction
AI-powered sentiment analysis and prediction trends for GERN, updated each market day.
GERN AI Sentiment
AI sees no strong directional signal for Geron Corp stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Geron Corp
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Sector
Exchange
Market Cap
$1,127,984,580
Cap Tier
Employees
258
Headquarters
FOSTER CITY, CA
Listed Since
July 31, 1996
Website
GERN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GERN Volatility
Geron Corp has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
